Drug intelligence / Profile preview

HUC1-394

Development stage: Unknown
Lead developer: Huons
Modality: Recombinant Proteins and Enzymes
Administration: Ophthalmic

Overview

HUC1-394 is a recombinant human protein-based ophthalmic solution being developed by Huons Co., Ltd. for the treatment of moderate to severe dry eye disease (DED). The therapeutic is designed to stabilize the tear film and promote the secretion of mucin, which helps protect the ocular surface and facilitate the repair of corneal epithelial damage. By enhancing the natural components of the tear film, HUC1-394 aims to provide a more comprehensive treatment for DED compared to standard lubricants. It is currently being evaluated in a Phase 2 clinical trial (NCT06116370) to determine the optimal dosing regimen and assess its efficacy and safety in adult participants.

Beyond the preview

Go deeper on HUC1-394.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUC1-394.

Explore the full profile